Adimmune (TPE:4142) Other Stockholders Equity: NT$172 Mil (As of Dec. 2025)


TPE:4142 Adimmune Corp TPE:4142
56 GF Score
Price NT$17.65
GF Value NT$25.65
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Adimmune Other Stockholders Equity?

Adimmune TPE:4142 56 Other Stockholders Equity is NT$172 Mil as of Dec. 2025. GuruFocus rates TPE:4142 with a GF Score™ of 56/100 and a GF Value™ of NT$25.65 (Possible Value Trap). The stock has 6 warning signs investors should review.

Adimmune's Other Stockholders Equity for the quarter that ended in Dec. 2025 was NT$172 Mil.

Adimmune's quarterly Other Stockholders Equity declined from Jun. 2025 (NT$188 Mil) to Sep. 2025 (NT$174 Mil) and declined from Sep. 2025 (NT$174 Mil) to Dec. 2025 (NT$172 Mil).

Adimmune's annual Other Stockholders Equity increased from Dec. 2023 (NT$185 Mil) to Dec. 2024 (NT$195 Mil) but then declined from Dec. 2024 (NT$195 Mil) to Dec. 2025 (NT$172 Mil).

Adimmune Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Adimmune's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adimmune Other Stockholders Equity Chart

Adimmune Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 166.07 151.16 184.72 195.27 172.02

Adimmune Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 195.27 187.33 187.95 174.45 172.02
TPE:4142
56GF Score
Adimmune Corp TPE:4142
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adimmune Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of NT$172 Mil mean?
Adimmune (TPE:4142) has a Other Stockholders Equity of NT$172 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Adimmune and its competitors.
Is Adimmune's Other Stockholders Equity too high?
Adimmune's current Other Stockholders Equity is NT$172 Mil. Overall, Adimmune has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Adimmune's Other Stockholders Equity compare to VRTX and REGN?
Adimmune's Other Stockholders Equity of NT$172 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Adimmune and its competitors. Adimmune's current Other Stockholders Equity is NT$172 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adimmune stock overvalued right now?
Based on GuruFocus' analysis, Adimmune (TPE:4142) is currently considered Possible Value Trap. The stock's GF Value™ is NT$25.65, compared to a current price of NT$17.65 — trading 31.2% below its estimated fair value. The current Other Stockholders Equity is NT$172 Mil. Adimmune's overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Adimmune (TPE:4142), the current Other Stockholders Equity is NT$172 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Adimmune (TPE:4142) Overvalued in 2026?

Based on GuruFocus' analysis, Adimmune stock appears to be undervalued. The current stock price of NT$17.65 is trading 31.2% below its estimated GF Value™ of NT$25.65. GuruFocus considers Adimmune to be Possible Value Trap.

Key valuation signals for TPE:4142:

  • Other Stockholders Equity: NT$172 Mil
  • GF Value™: NT$25.65 vs. price of NT$17.65 (31.2% below fair value)
  • GF Score™: 56/100 with 6 warning signs

No single metric tells the full story. See the TPE:4142 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Adimmune Business Description

Address Tanxing Road, No. 3, Section 1, Tanzi District, Taichung City, TWN, 427003
Adimmune Corp is engaged in the research and development, processing, manufacturing, and trading of serum, vaccines, testing reagents, biologicals, and other bacterial fluids, as well as western medicines, animal medicines, chemicals, and feed additives. Its segments are separated by business as Adimmune Corporation, which generates maximum revenue and is engaged in the manufacturing of influenza vaccines with EU GMP and US FDA certificates in Taiwan. Its products include Trivalent Influenza Vaccine, Quadrivalent Influenza Vaccine, Influenza A (H1N1) Virus Monovalent Vaccine, and others, and Enimmune Corporation. The Group's revenue is mainly from the manufacturing and trading of vaccines, modern medicine products and testing reagents, as well as entrusted packing of vaccines.
56GF Score

Get the complete analysis for TPE:4142

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$17.65
Price
NT$25.65
GF Value